NO20002005L - FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel - Google Patents

FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel

Info

Publication number
NO20002005L
NO20002005L NO20002005A NO20002005A NO20002005L NO 20002005 L NO20002005 L NO 20002005L NO 20002005 A NO20002005 A NO 20002005A NO 20002005 A NO20002005 A NO 20002005A NO 20002005 L NO20002005 L NO 20002005L
Authority
NO
Norway
Prior art keywords
treatment
protein
deficiency
procedure
apc
Prior art date
Application number
NO20002005A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002005D0 (no
Inventor
Brian William Grinnell
Daniel Lawrence Hartman
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20002005D0 publication Critical patent/NO20002005D0/no
Publication of NO20002005L publication Critical patent/NO20002005L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20002005A 1997-10-20 2000-04-17 FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel NO20002005L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07
PCT/US1998/021723 WO1999020293A1 (en) 1997-10-20 1998-10-14 Methods for treating hypercoagulable states or acquired protein c deficiency

Publications (2)

Publication Number Publication Date
NO20002005D0 NO20002005D0 (no) 2000-04-17
NO20002005L true NO20002005L (no) 2000-05-16

Family

ID=26742406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002005A NO20002005L (no) 1997-10-20 2000-04-17 FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel

Country Status (28)

Country Link
US (7) US6037322A (hu)
EP (2) EP1449537A3 (hu)
JP (2) JP3805981B2 (hu)
KR (1) KR100798174B1 (hu)
CN (1) CN1276726A (hu)
AT (1) ATE292979T1 (hu)
AU (1) AU748417B2 (hu)
BR (1) BR9812965A (hu)
CA (1) CA2306983A1 (hu)
DE (1) DE69829721T2 (hu)
DK (1) DK0913156T3 (hu)
EA (1) EA002496B1 (hu)
ES (1) ES2239382T3 (hu)
HK (1) HK1020529A1 (hu)
HU (2) HUP0001237A3 (hu)
ID (1) ID24901A (hu)
IL (2) IL135712A0 (hu)
MY (1) MY117655A (hu)
NO (1) NO20002005L (hu)
NZ (1) NZ504026A (hu)
PL (1) PL200515B1 (hu)
PT (1) PT913156E (hu)
SI (1) SI0913156T1 (hu)
TR (1) TR200001059T2 (hu)
TW (1) TWI225404B (hu)
UA (1) UA72194C2 (hu)
WO (1) WO1999020293A1 (hu)
ZA (1) ZA989385B (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2288143C (en) 1997-04-28 2012-08-21 Eli Lilly And Company Activated protein c formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
BR9914735A (pt) 1998-10-22 2001-07-03 Lilly Co Eli Processo para tratamento de sépsia
BR9915317A (pt) * 1998-11-13 2001-08-07 Lilly Co Eli Método de tratar trombocitopenia induzida por heparina
EP1133314B1 (en) * 1998-11-23 2003-02-19 Eli Lilly And Company Protein c for the treatment of sickle cell disease and thalassemia
WO2001056532A2 (en) * 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6736972B1 (en) 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
EP1267915B1 (en) * 2000-03-28 2005-06-22 Eli Lilly And Company Activated protein c for treating pancreatitis
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
EP1289543A2 (en) * 2000-05-24 2003-03-12 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
CA2438652A1 (en) 2001-02-19 2002-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
WO2002100445A1 (en) * 2001-06-13 2002-12-19 The University Of Sydney Treatment and composition for wound healing
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
MXPA04003547A (es) 2001-10-15 2004-07-22 Chiron Corp Tratamiento de sepsis mediante administracion de dosis bajas de inhibidor de via factor de tejido.
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
WO2003075834A2 (en) * 2002-03-08 2003-09-18 Eli Lilly And Company Activated protein c formulations
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
US20060129082A1 (en) * 2002-08-13 2006-06-15 Jacek Rozga Selective plasma exchange therapy
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
EP1598368A4 (en) * 2003-01-20 2007-07-25 Chugai Pharmaceutical Co Ltd ANTI-PCI neutralizing ANTIBODY
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2004103294A2 (en) 2003-05-15 2004-12-02 Tanox, Inc. Methods and compositions for the prevention and treatment of sepsis
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
JP4986618B2 (ja) 2003-07-08 2012-07-25 ザ スクリプス リサーチ インスティチュート 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
US20090227669A1 (en) * 2004-01-23 2009-09-10 The University Of Toledo Compositions and Methods for Perioperative Bladder Instillation
CN101426520A (zh) * 2004-03-17 2009-05-06 诺华疫苗和诊断公司 通过给予组织因子途径抑制剂（tfpi）治疗社区获得性重症肺炎
EP1745145A4 (en) * 2004-05-11 2008-03-26 Heptest Lab Inc COMPOSITIONS, KIT AND METHOD IN ONE STEP FOR MONITORING COMPOUNDS HAVING XA AND / OR ANTIFACTOR IIA ANTIFACTOR ACTIVITIES
EP1773371A4 (en) * 2004-07-23 2009-12-30 Univ Rochester ACTIVATED PROTEIN C INHIBITS SIDE EFFECTS OF PLASMINOGEN ACTIVATOR IN THE BRAIN
US9107917B2 (en) * 2005-05-13 2015-08-18 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2A adrenergic antagonists
JP2008543926A (ja) * 2005-06-24 2008-12-04 ダラグレキュル・アンパルトセルスカブ 呼吸器系に影響を及ぼす炎症状態における活性化プロテインｃの気道投与
AU2006266609C1 (en) 2005-07-05 2011-10-27 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
RU2490722C1 (ru) * 2012-04-24 2013-08-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ восстановления кровотока в регионе тромбированной вены в эксперименте
WO2014005183A1 (en) 2012-07-04 2014-01-09 The University Of Sydney Treatment of inflammatory skin disorders
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
WO2019238787A1 (en) 2018-06-15 2019-12-19 Ab Sandvik Materials Technology A duplex stainless steel strip and method for producing thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3434326B2 (ja) * 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 成人呼吸窮迫症候群（ａｒｄｓ）予防、治療剤
JP2825739B2 (ja) * 1993-09-20 1998-11-18 帝人株式会社 急性肝不全治療剤
JP3802104B2 (ja) * 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
CA2288143C (en) * 1997-04-28 2012-08-21 Eli Lilly And Company Activated protein c formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
DE69829721T2 (de) 2006-02-09
CA2306983A1 (en) 1999-04-29
TWI225404B (en) 2004-12-21
HK1020529A1 (en) 2000-05-12
ZA989385B (en) 2000-04-14
US20010036456A1 (en) 2001-11-01
US6268337B1 (en) 2001-07-31
US6156734A (en) 2000-12-05
BR9812965A (pt) 2001-03-20
MY117655A (en) 2004-07-31
EP1449537A2 (en) 2004-08-25
US6426071B2 (en) 2002-07-30
HUP0001237A2 (hu) 2000-08-28
CN1276726A (zh) 2000-12-13
EP1449537A3 (en) 2005-09-21
AU9804098A (en) 1999-05-10
PL340096A1 (en) 2001-01-15
NZ504026A (en) 2002-12-20
SI0913156T1 (en) 2005-10-31
PL200515B1 (pl) 2009-01-30
EP0913156A1 (en) 1999-05-06
US6489296B1 (en) 2002-12-03
ATE292979T1 (de) 2005-04-15
NO20002005D0 (no) 2000-04-17
KR20010031217A (ko) 2001-04-16
JP2001520199A (ja) 2001-10-30
JP2005097313A (ja) 2005-04-14
IL135712A0 (en) 2001-05-20
US6008199A (en) 1999-12-28
EA200000445A1 (ru) 2000-10-30
HUP0100025A3 (en) 2003-08-28
US6268344B1 (en) 2001-07-31
IL135712A (en) 2010-12-30
PT913156E (pt) 2005-08-31
HUP0001237A3 (en) 2002-01-28
ES2239382T3 (es) 2005-09-16
WO1999020293A1 (en) 1999-04-29
US6037322A (en) 2000-03-14
TR200001059T2 (tr) 2000-10-23
EA002496B1 (ru) 2002-06-27
JP3805981B2 (ja) 2006-08-09
HUP0100025A2 (hu) 2001-05-28
DK0913156T3 (da) 2005-06-27
UA72194C2 (en) 2005-02-15
AU748417B2 (en) 2002-06-06
HU224901B1 (en) 2006-04-28
EP0913156B1 (en) 2005-04-13
KR100798174B1 (ko) 2008-01-24
DE69829721D1 (de) 2005-05-19
ID24901A (id) 2000-08-31

Similar Documents

Publication Publication Date Title
NO20002005L (no) FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel
DE69722401D1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ATE295176T1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
EP0376251A3 (en) An anticoagulant substance obtained from urine
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AU3401093A (en) Therapeutic agent for threatened abortion
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
Murray Review of international safety data for lisinopril-hydrochlorothiazide combination treatment
al-Shukri et al. The effect of prostatilen on the hemostatic indices in chronic prostatitis (a clinical and experimental study)
TH76071A (th) สารผสมสำหรับการบำบัดรักษาการตกเลือด ที่มีแฟกเตอร์ viia ที่ถูกกระตุ้นในการรวมกันด้วย ไฟบริโนเจน และวิธีการใช้สารนี้
UA7180C2 (uk) Препарат для лікування та профілактики атерогенних дисліпопротеїнемій та синдрому гіперкоагуляції
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
UA43258A (uk) Спосіб лікування онкологичних хвороб
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту
UA40717A (uk) Спосіб лікування хворих з шлунковою кровотечею
HUP9903911A2 (hu) PKC inhibitorok alkalmazása a központi idegrendszer HIV-fertőzéssel kapcsolatos megbetegedéseinek kezelésére szolgáló gyógyászati készítmények előállítására
MX9603241A (es) Productos farmaceuticos para curar enfermedades tumorales y procedimiento para su preparacion.
TH44144A (th) วิธีสำหรับรักษาความผิดปกติของหลอดเลือด

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application